rs80358932

Variant summary

Our verdict is Benign. Variant got -12 ACMG points: 0P and 12B. BP4_StrongBP6_Very_Strong

The NM_000059.4(BRCA2):ā€‹c.7052C>Gā€‹(p.Ala2351Gly) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000719 in 1,613,572 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 12/19 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (ā˜…ā˜…). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. A2351S) has been classified as Likely benign.

Frequency

Genomes: š‘“ 0.000079 ( 0 hom., cov: 32)
Exomes š‘“: 0.000071 ( 1 hom. )

Consequence

BRCA2
NM_000059.4 missense

Scores

4
12

Clinical Significance

Benign/Likely benign criteria provided, multiple submitters, no conflicts U:1B:22O:1

Conservation

PhyloP100: 0.00500
Variant links:
Genes affected
BRCA2 (HGNC:1101): (BRCA2 DNA repair associated) Inherited mutations in BRCA1 and this gene, BRCA2, confer increased lifetime risk of developing breast or ovarian cancer. Both BRCA1 and BRCA2 are involved in maintenance of genome stability, specifically the homologous recombination pathway for double-strand DNA repair. The largest exon in both genes is exon 11, which harbors the most important and frequent mutations in breast cancer patients. The BRCA2 gene was found on chromosome 13q12.3 in human. The BRCA2 protein contains several copies of a 70 aa motif called the BRC motif, and these motifs mediate binding to the RAD51 recombinase which functions in DNA repair. BRCA2 is considered a tumor suppressor gene, as tumors with BRCA2 mutations generally exhibit loss of heterozygosity (LOH) of the wild-type allele. [provided by RefSeq, May 2020]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Benign. Variant got -12 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.007881105).
BP6
Variant 13-32354905-C-G is Benign according to our data. Variant chr13-32354905-C-G is described in ClinVar as [Likely_benign]. Clinvar id is 38081.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr13-32354905-C-G is described in Lovd as [Likely_benign]. Variant chr13-32354905-C-G is described in Lovd as [Benign].

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE Protein UniProt
BRCA2NM_000059.4 linkuse as main transcriptc.7052C>G p.Ala2351Gly missense_variant 14/27 ENST00000380152.8 NP_000050.3

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Protein Appris UniProt
BRCA2ENST00000380152.8 linkuse as main transcriptc.7052C>G p.Ala2351Gly missense_variant 14/275 NM_000059.4 ENSP00000369497 A2

Frequencies

GnomAD3 genomes
AF:
0.0000789
AC:
12
AN:
152178
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00212
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00
Gnomad OTH
AF:
0.000479
GnomAD3 exomes
AF:
0.000156
AC:
39
AN:
250774
Hom.:
0
AF XY:
0.000155
AC XY:
21
AN XY:
135624
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00207
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00
Gnomad OTH exome
AF:
0.000164
GnomAD4 exome
AF:
0.0000712
AC:
104
AN:
1461276
Hom.:
1
Cov.:
31
AF XY:
0.0000729
AC XY:
53
AN XY:
726932
show subpopulations
Gnomad4 AFR exome
AF:
0.00
Gnomad4 AMR exome
AF:
0.00
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00209
Gnomad4 SAS exome
AF:
0.00
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.00000180
Gnomad4 OTH exome
AF:
0.000315
GnomAD4 genome
AF:
0.0000788
AC:
12
AN:
152296
Hom.:
0
Cov.:
32
AF XY:
0.0000806
AC XY:
6
AN XY:
74468
show subpopulations
Gnomad4 AFR
AF:
0.00
Gnomad4 AMR
AF:
0.00
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00212
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.00
Gnomad4 OTH
AF:
0.000474
Alfa
AF:
0.000142
Hom.:
1
Bravo
AF:
0.0000945
ExAC
AF:
0.000132
AC:
16
Asia WGS
AF:
0.00115
AC:
4
AN:
3478

ClinVar

Significance: Benign/Likely benign
Submissions summary: Uncertain:1Benign:22Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Benign:7
Benign, criteria provided, single submitterclinical testingQuest Diagnostics Nichols Institute San Juan CapistranoJul 31, 2023- -
Likely benign, criteria provided, single submitterclinical testingGeneDxNov 25, 2020This variant is associated with the following publications: (PMID: 21990134, 20104584, 21990165, 28664449, 27658390, 24728327, 16949048, 21218378, 18824701, 17100994, 18006916, 21520273, 28222693, 27124784, 27150160, 21120943, 18779604, 26435481, 29731985, 28678401, 27907908, 29020732, 30415210, 28111427, 30093976, 31131967, 31825140) -
Benign, criteria provided, single submitterclinical testingWomen's Health and Genetics/Laboratory Corporation of America, LabCorpMar 21, 2016Variant Summary: The BRCA2 variant of interest causes a missense change involving a non-conserved nucleotide with 2/4 in silico programs predicting a "benign" outcome (SNPs&Go not captured here due to low reliability index), although these predictions have yet to be functionally assessed. The variant of interest was observed in a large, broad control population, ExAC with an allele frequency of 16/120976 (1/7561), predominantly in the East Asian cohort, 15/8648 (1/577), which significantly exceeds the maximal expected allele frequency for a pathogenic BRCA2 variant of 1/1333, therefore suggesting the variant of interest is a common polymorphism found in population(s) of East Asian origin. The variant of interest has been reported in affected individuals via publicatins, predominantly in those of Asian decent, although limited information is provided (i.e. lack of co-occurrence and co-segregation information being provided). The variant of interest has been reported by multiple reputable databases/clinical laboratories as "likely benign/benign." Additionally, the BIC database reports one individual with a pathogenic BRCA2 co-occurrence, c.1103C>A (p.Ser368Ter). Therefore, taking all lines of evidence into consideration, the variant of interest is classified as benign. -
Likely benign, no assertion criteria providedclinical testingClinical Genetics Laboratory, Department of Pathology, Netherlands Cancer Institute-- -
Likely benign, no assertion criteria providedclinical testingLaboratory of Diagnostic Genome Analysis, Leiden University Medical Center (LUMC)-- -
Likely benign, no assertion criteria providedclinical testingMayo Clinic Laboratories, Mayo ClinicFeb 20, 2017- -
Likely benign, no assertion criteria providedclinical testingJoint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+-- -
Breast-ovarian cancer, familial, susceptibility to, 2 Uncertain:1Benign:5
Likely benign, no assertion criteria providedclinical testingPathway GenomicsJul 24, 2014- -
Benign, no assertion criteria providedclinical testingSharing Clinical Reports Project (SCRP)May 01, 2012- -
Uncertain significance, no assertion criteria providedclinical testingBreast Cancer Information Core (BIC) (BRCA2)May 29, 2002- -
Likely benign, criteria provided, single submitterclinical testingIllumina Laboratory Services, IlluminaApr 27, 2017This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. The evidence from the literature, in combination with allele frequency data from public databases where available, was sufficient to determine this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign. -
Likely benign, criteria provided, single submitterclinical testingGenome Diagnostics Laboratory, University Medical Center UtrechtOct 09, 2014- -
Likely benign, criteria provided, single submitterclinical testingClinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical CenterSep 21, 2015- -
Hereditary cancer-predisposing syndrome Benign:3
Likely benign, criteria provided, single submittercurationSema4, Sema4Jul 13, 2021- -
Likely benign, criteria provided, single submitterclinical testingAmbry GeneticsAug 14, 2018This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
Benign, criteria provided, single submitterclinical testingColor Diagnostics, LLC DBA Color HealthDec 02, 2015- -
not specified Benign:2Other:1
not provided, no classification providedreference populationITMISep 19, 2013- -
Benign, criteria provided, single submitterclinical testingARUP Laboratories, Molecular Genetics and Genomics, ARUP LaboratoriesDec 05, 2016- -
Likely benign, criteria provided, single submitterclinical testingGenetic Services Laboratory, University of ChicagoAug 27, 2019- -
Breast and/or ovarian cancer Benign:1
Likely benign, criteria provided, single submitterclinical testingCHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern OntarioApr 19, 2021- -
Fanconi anemia complementation group D1 Benign:1
Likely benign, criteria provided, single submitterclinical testingIllumina Laboratory Services, IlluminaApr 27, 2017This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases allowed determination this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign. -
Malignant tumor of breast Benign:1
Benign, no assertion criteria providedclinical testingDepartment of Pathology and Laboratory Medicine, Sinai Health System-- -
Familial cancer of breast Benign:1
Likely benign, no assertion criteria providedliterature onlyCenter for Precision Medicine, Meizhou People's Hospital-- -
Hereditary breast ovarian cancer syndrome Benign:1
Benign, criteria provided, single submitterclinical testingLabcorp Genetics (formerly Invitae), LabcorpJan 31, 2024- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.13
BayesDel_addAF
Benign
-0.32
T
BayesDel_noAF
Benign
-0.24
CADD
Benign
13
DANN
Uncertain
0.98
Eigen
Benign
-0.36
Eigen_PC
Benign
-0.44
FATHMM_MKL
Benign
0.11
N
M_CAP
Uncertain
0.10
D
MetaRNN
Benign
0.0079
T;T
MetaSVM
Benign
-0.76
T
MutationTaster
Benign
1.0
N;N
PrimateAI
Benign
0.20
T
PROVEAN
Benign
-1.1
N;N
REVEL
Uncertain
0.41
Sift
Uncertain
0.011
D;D
Sift4G
Benign
0.082
T;T
Vest4
0.21
MutPred
0.19
Gain of disorder (P = 0.0561);Gain of disorder (P = 0.0561);
MVP
0.88
MPC
0.059
ClinPred
0.072
T
GERP RS
2.0
gMVP
0.17

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs80358932; hg19: chr13-32929042; COSMIC: COSV66454187; API